CORC

在结果中检索

CORC

浏览/检索结果: 共206条，第1-10条 帮助

限定条件                
已选(0)清除 条数/页：   排序方式：
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study 期刊论文
2019, 卷号: 8, 期号: 13, 页码: 5823-5830
作者:  Yang Guangjian;  Ma Di;  Xu Haiyan;  Yang Lu;  Li Junling
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03
RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) 会议论文
ANNALS OF ONCOLOGY, 2019-04-01
作者:  Paz-Ares, L.;  Senan, S.;  Planchard, D.;  Wang, L.;  Cheong, A.
收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03
RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) 期刊论文
2019, 卷号: 30, 页码: 67-67
作者:  Paz-Ares, L.;  Senan, S.;  Planchard, D.;  Wang, L.;  Cheong, A.
收藏  |  浏览/下载：12/0  |  提交时间：2020/01/03
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer 期刊论文
2019, 卷号: 11, 页码: 7707-7719
作者:  Liang, Hongge;  Wang, Mengzhao
收藏  |  浏览/下载：12/0  |  提交时间：2020/01/03
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy 期刊论文
2019, 卷号: 39, 期号: 1, 页码: 36
作者:  Zhou, Ming;  Chen, Xiaoyuan;  Zhang, Hong;  Xia, Lin;  Tong, Xin
收藏  |  浏览/下载：29/0  |  提交时间：2020/01/03
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study 期刊论文
2019, 卷号: 31, 期号: 3, 页码: 481-+
作者:  Xing, Puyuan;  Ma, Di;  Wang, Qiang;  Hao, Xuezhi;  Wang, Mengzhao
收藏  |  浏览/下载：15/0  |  提交时间：2020/01/03
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study 期刊论文
2019, 卷号: 10, 期号: 7, 页码: 1521-1532
作者:  Liang Hongge;  Song Xia;  Zhang Yuhui;  Zhang Shucai;  Li Fang
收藏  |  浏览/下载：31/0  |  提交时间：2020/01/03
Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment 期刊论文
2019, 卷号: 31, 期号: 2, 页码: 349-356
作者:  Xu, Haiyan;  Ma, Di;  Yang, Guangjian;  Li, Junling;  Hao, Xuezhi
收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib 期刊论文
2019, 卷号: 14, 期号: 3, 页码: 335-342
作者:  Mu, Yuxin;  Hao, Xuezhi;  Yang, Ke;  Ma, Di;  Wang, Shouzheng
收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03
Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China 期刊论文
2019, 卷号: 14, 期号: 3, 页码: 325-333
作者:  Xing, Puyuan;  Wang, Shouzheng;  Wang, Qiang;  Ma, Di;  Hao, Xuezhi
收藏  |  浏览/下载：11/0  |  提交时间：2020/01/03

©版权所有 ©2017 CSpace - Powered by CSpace